NOTCH3 and migraine disorder: Compared with 3252 CADASIL patients from 22 studies, the prevalence of stroke was almost the same as in patients with NOTCH3 cysteine-sparing mutations (61.65% vs. 62.37%), and the prevalence of migraine (49.05% vs. 43.48%) as well.